clinical trial · NCT03559686
Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)
UCB Biopharma SRL·—·available
Rheumatoid ArthritisCertolizumab Pegol
brief summary
The objective of this Named Patient Program (NPP) is to provide continued availability of Certolizumab Pegol (CZP) to adult Rheumatoid Arthritis (RA) patients who participated in the open label studies C87015 (CDP870 015), C87028 (CDP870-028) and C87051 (CDP870-051). Physicians may use the option to continue offering patients CZP treatment or to transition patients off CZP to a standard care regimen.
started
—
primary completion
—
completion
—
last updated
Jun 8, 2025
official title
Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Arthritis (RA) Who Participated in Open Label Studies C87015, C87028 and C87051
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol